BioCentury | Mar 16, 2021
Product Development

The clinical pipeline for Alzheimer’s disease: Data Byte

Although amyloid-lowering agents still represent the lion’s share of late-stage candidates for Alzheimer’s disease, they account for less than 20% of compounds across all clinical stages. Tau inhibition, modulation of neurotransmitter signaling, and quelling of...
BioCentury | Mar 5, 2021

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

A year to the day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. raised $117 million in a series B round led by Viking Global Investors...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | May 4, 2020

Stemline takeout gives Menarini U.S. oncology beachhead

Although Menarini will gain a modest-selling drug by acquiring Stemline for up to $677 million, the Italian biopharma will also establish a U.S. oncology presence as its cancer pipeline matures. The deal gives Menarini Group...
BioCentury | Apr 14, 2020

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a...
BioCentury | Mar 26, 2020

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

Abbisko raises $70M series C Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo. The company's...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 30, 2020
Distillery Therapeutics

HDAC3 identified as obesity target

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Intestinal HDAC3 inhibition could treat obesity. In mice fed a normal diet, intestinal knockout of HDAC3 increased intestinal expression of lipid metabolism genes. In a mouse model of obesity induced...
BioCentury | Dec 12, 2019

HDAC9 identified as target in atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Inhibiting HDAC9 could treat atherosclerosis by reducing vascular calcification, one of the disease's hallmarks. Six SNPs for which HDAC9 is the nearest gene were associated with abdominal aortic calcification in...
Items per page:
1 - 10 of 1045